



友邦保险

友邦人寿保险有限公司

## 友邦海外特药医疗保险-特定药品列表

2025年12月 (V2.0版)

### 说明:

1、本公司将根据特定药品临床应用的发展，跟踪分析并适时更新和公布本《特定药品列表》，本列表以本公司官网（<https://www.aia.com.cn/zh-cn/fuwu/yiyaopilu>）的最新公布信息为准，以下特种药品清单有效期间自2026年1月1日至2026年12月31日，您也可通过服务热线（400-005-7995）进行查询和了解。

2、本列表所含药品，须严格按照治疗地的医疗或药品监督管理机构（释义一）批准的适应症凭治疗地执业医师的处方使用。

释义一 医疗或药品监督管理机构：指所在国或地区负责监管药品、医疗器械、食品安全以及相关公共卫生事项的行政机构，各国有不同的监督管理机构。例如：美国食品药品监督管理局（FDA: Food and Drug Administration）欧洲药品管理局（EMA: European Medicines Agency）；日本医药品医疗器械管理局（PMDA: Pharmaceuticals and Medical Devices Agency）等。

序号	通用名/商品名 (按通用名字母顺序排序)	适应症 (若中文与英文适应症不一致, 以英文为准)	恶性肿瘤 -重度类型
1	Adagrasib/Krazati	Indicated for: ※ As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.	适用于： ※ 作为单药，治疗经FDA批准的检测确认为KRAS G12C突变的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者，患者既往至少接受过一线全身治疗。
		Indicated for: ※ In combination with cetuximab, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC), as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.	适用于： ※ 联合西妥昔单抗（cetuximab），治疗经FDA批准的检测确定为KRAS G12C突变的局部晚期或转移性结直肠癌（CRC）成人患者，且患者既往已接受过以氟嘧啶、奥沙利铂和伊立替康为基础的化疗。
2	Afamitresgene Autoleucel/ Tecelra	Indicated for: ※ The treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices.	适用于： ※ 治疗既往接受过化疗的不可切除或转移性滑膜肉瘤成人患者，患者的HLA-A*02:01P、-A*02:02P、-A*02:03P或-A*02:06P型为阳性，且其肿瘤经FDA批准或许可的伴随诊断设备检测确认表达MAGE-A4抗原。
3	Alpelisib/Piqray	Indicated for: ※ In combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer	适用于： ※ 联合氟维司群，治疗激素受体（HR）阳性、人表皮生长因子受体2（HER2）阴性、PIK3CA突变的晚期或转移性乳腺癌成人患者，患

		as detected by an FDA-approved test following progression on or after an endocrine-based regimen.	者在内分泌治疗方案中或治疗后出现疾病进展并经FDA批准的检测确认。	
4	Asciminib/Scemblix	<p>Indicated for:</p> <ul style="list-style-type: none"> <li>※ The treatment of adult patients with:           <ul style="list-style-type: none"> <li>• Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).</li> <li>• Previously treated Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).</li> <li>• Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I mutation.</li> </ul> </li> </ul>	<p>适用于:</p> <p>※ 治疗患有以下疾病的成人患者:</p> <ul style="list-style-type: none"> <li>• 新诊断的慢性期 (CP) 费城染色体阳性慢性髓性白血病 (Ph+ CML)。</li> <li>• 既往接受过治疗的慢性期 (CP) 费城染色体阳性慢性髓性白血病 (Ph+ CML)。</li> <li>• T315I突变的慢性期 (CP) 费城染色体阳性慢性髓性白血病 (Ph+ CML)。</li> </ul>	慢性髓性白血病
5	Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn/Rylaze	<p>Indicated for:</p> <ul style="list-style-type: none"> <li>※ As a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.</li> </ul>	<p>适用于:</p> <p>※ 作为联合化疗方案的组成部分, 治疗急性淋巴细胞白血病 (ALL) 和淋巴母细胞淋巴瘤 (LBL) 的成人和1个月及以上儿童患者, 患者对源自大肠杆菌的门冬酰胺酶存在超敏反应。</p>	急性淋巴细胞白血病/淋巴母细胞淋巴瘤
6	Avelumab/Bavencio	<p>Indicated for:</p> <ul style="list-style-type: none"> <li>※ Adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC).</li> </ul>	<p>适用于:</p> <p>※ 治疗转移性Merkel细胞癌 (MCC) 的成人和12岁及以上儿童患者。</p>	Merkel细胞癌
		<p>Indicated for:</p> <ul style="list-style-type: none"> <li>※ Maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy.</li> <li>※ Patients with locally advanced or metastatic urothelial carcinoma (UC) who:           <ul style="list-style-type: none"> <li>• Have disease progression during or following platinum-containing chemotherapy.</li> <li>• Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.</li> </ul> </li> </ul>	<p>适用于:</p> <p>※ 一线含铂化疗后疾病未进展的局部晚期或转移性尿路上皮癌 (UC) 患者的维持治疗。</p> <p>※ 符合以下条件的局部晚期或转移性尿路上皮癌 (UC) 患者:</p> <ul style="list-style-type: none"> <li>• 在含铂化疗期间或之后疾病进展。</li> <li>• 在含铂新辅助化疗或辅助化疗后12个月内疾病进展。</li> </ul>	尿路上皮癌
		<p>Indicated for:</p> <ul style="list-style-type: none"> <li>※ First-line treatment, in combination with axitinib, of patients with advanced renal cell carcinoma (RCC).</li> </ul>	<p>适用于:</p> <p>※ 联合阿昔替尼, 一线治疗晚期肾细胞癌 (RCC) 患者。</p>	肾细胞癌
7	Belinostat/Beleodaq	<p>Indicated for:</p> <ul style="list-style-type: none"> <li>※ The treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).</li> </ul>	<p>适用于:</p> <p>※ 治疗复发或难治性外周T细胞淋巴瘤 (PTCL) 的成人患者。</p>	外周T细胞淋巴瘤



8	Binimatinib/Mektovi	Indicated for: ※ In combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.	适用于: ※ 联合恩考芬尼，治疗经 FDA 批准的检测确认为 BRAF V600E 或 V600K 突变的不可切除或转移性黑色素瘤患者。	黑色素瘤
		Indicated for: ※ In combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.	适用于: ※ 联合恩考芬尼，治疗经 FDA 批准的检测确认为 BRAF V600E 突变的转移性非小细胞肺癌 (NSCLC) 成人患者。	非小细胞肺癌
9	Bosutinib/Bosulif	Indicated for: ※ The treatment of adult and pediatric patients 1 year of age and older with chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy.  ※ The treatment of adult patients with accelerated, or blast phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) with resistance or intolerance to prior therapy.	适用于: ※ 治疗新确诊或对既往治疗耐药或不耐受的慢性期 (CP) 费城染色体阳性慢性髓性白血病 (Ph+ CML) 成人和 1 岁及以上儿童患者。  ※ 治疗对既往治疗耐药或不耐受的加速期 (AP) 或急变期 (BP) 费城染色体阳性慢性髓性白血病 (Ph+ CML) 成人患者。	慢性髓性白血病
10	Brexcucabtagene Autoleucel/Tecartus	Indicated for: ※ The treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).	适用于: ※ 治疗复发或难治性 B 细胞前体急性淋巴细胞白血病 (ALL) 成人患者。	急性淋巴细胞白血病
		Indicated for: ※ The treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).	适用于: ※ 治疗复发或难治性套细胞淋巴瘤 (MCL) 成人患者。	套细胞淋巴瘤
11	Cabazitaxel/Jevtana	Indicated for: ※ In combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen.	适用于: ※ 联合泼尼松，治疗既往接受过含多西他赛方案治疗的转移性去势抵抗性前列腺癌患者。	前列腺癌
12	Cabozantinib/Cabometyx	Indicated for: ※ The treatment of patients with advanced renal cell carcinoma (RCC).  ※ The treatment of patients with advanced renal cell carcinoma, as a first-line treatment in combination with nivolumab.	适用于: ※ 治疗晚期肾细胞癌 (RCC) 患者。  ※ 联合纳武单抗，一线治疗治疗晚期肾细胞癌 (RCC) 患者。	肾细胞癌
		Indicated for: ※ The treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.	适用于: ※ 治疗既往接受过索拉非尼治疗的肝细胞癌 (HCC) 患者。	肝细胞癌
		Indicated for:	适用于:	分化型甲状腺癌

		<p>※ The treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible.</p> <p>Indicated for:</p> <p>※ The treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET).</p> <p>Indicated for:</p> <p>※ The treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic neuroendocrine tumors (epNET).</p>	<p>※ 治疗局部晚期或转移性分化型甲状腺癌 (DTC) 的成人和12岁及以上儿童患者，患者在既往接受过VEGFR靶向治疗后疾病进展，且放射性碘难治或不符合条件。</p> <p>适用于：</p> <p>※ 治疗既往接受过治疗、不可切除的局部晚期或转移性、高分化的胰腺神经内分泌肿瘤 (pNET) 的成人和12岁及以上儿童患者。</p> <p>适用于：</p> <p>※ 治疗既往接受过治疗、不可切除的局部晚期或转移性、高分化的胰腺外神经内分泌肿瘤 (epNET) 的成人和12岁及以上儿童患者。</p>	
13	Cabozantinib/Cometriq	<p>Indicated for:</p> <p>※ The treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).</p>	<p>适用于：</p> <p>※ 治疗进展性转移性甲状腺髓样癌 (MTC) 患者。</p>	甲状腺髓样癌
14	Cemiplimab-rwlc/Libtayo	<p>Indicated for:</p> <p>※ In combination with platinum - based chemotherapy for the first - line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is:</p> <ul style="list-style-type: none"> <li>Locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or</li> <li>Metastatic.</li> </ul> <p>※ As single agent for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) <math>\geq 50\%</math>] as determined by an FDA-approved test, with no EGFR, ALK, or ROS1 aberrations, and is:</p> <ul style="list-style-type: none"> <li>Locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or</li> <li>Metastatic.</li> </ul>	<p>适用于：</p> <p>※ 联合含铂化疗，一线治疗符合以下条件的无EGFR、ALK或ROS1突变的非小细胞肺癌 (NSCLC) 成人患者：</p> <ul style="list-style-type: none"> <li>局部晚期的，不适合手术切除或根治性放化疗，或</li> <li>转移性的。</li> </ul> <p>※ 作为单药，一线治疗非小细胞肺癌 (NSCLC) 成人患者，患者的肿瘤具有高PD-L1表达【肿瘤细胞阳性比例评分 (TPS) <math>\geq 50\%</math>】(经 FDA 批准的检测确认)，且无EGFR、ALK或ROS1突变，并且符合以下条件：</p> <ul style="list-style-type: none"> <li>局部晚期的，不适合手术切除或根治性放化疗，或</li> <li>转移性的。</li> </ul>	非小细胞肺癌
		<p>Indicated for:</p> <p>※ The treatment of adult patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced cutaneous squamous cell carcinoma (laCSCC) who are not candidates for curative surgery or curative radiation.</p>	<p>适用于：</p> <p>※ 治疗不适合根治性手术或根治性放疗的转移性皮肤鳞状细胞癌 (mCSCC) 或局部晚期皮肤鳞状细胞癌 (laCSCC) 的成人患者。</p>	皮肤鳞状细胞癌



		<p>Indicated for:</p> <p>※ The treatment of adult patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate.</p>	<p>适用于:</p> <p>※ 治疗既往接受过 Hedgehog 信号通路抑制剂治疗或不适合 Hedgehog 信号通路抑制剂治疗的局部晚期或转移性基底细胞癌 (laBCC 或 mBCC) 成人患者。</p>	基底细胞癌
15	Cobimetinib/Cotellie	<p>Indicated for:</p> <p>※ The treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.</p>	<p>适用于:</p> <p>※ 联合维莫非尼, 治疗 BRAF V600E 或 V600K 突变的不可切除或转移性黑色素瘤成人患者。</p>	黑色素瘤
		<p>Indicated for:</p> <p>※ As a single agent for the treatment of adult patients with histiocytic neoplasms.</p>	<p>适用于:</p> <p>※ 作为单药, 治疗组织细胞肿瘤成人患者。</p>	组织细胞肿瘤
16	Cosibelimab-ipdl/Unloxcyt	<p>Indicated for:</p> <p>※ The treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced cutaneous squamous cell carcinoma (laCSCC) who are not candidates for curative surgery or curative radiation.</p>	<p>适用于:</p> <p>※ 治疗不适合根治性手术或根治性放疗的转移性皮肤鳞状细胞癌 (mCSCC) 或局部晚期皮肤鳞状细胞癌 (laCSCC) 成人患者。</p>	皮肤鳞状细胞癌
17	Datopotamab Deruxtecan-dlnk/Datroway	<p>Indicated for:</p> <p>※ The treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy.</p>	<p>适用于:</p> <p>※ 治疗既往接受过表皮生长因子受体 (EGFR) 靶向治疗及含铂化疗的局部晚期或转移性EGFR突变型非小细胞肺癌 (NSCLC) 成人患者。</p>	非小细胞肺癌
		<p>Indicated for:</p> <p>※ The treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.</p>	<p>适用于:</p> <p>※ 治疗激素受体 (HR) 阳性、人表皮生长因子受体 2 (HER2) 阴性 (IHC 0、IHC 1+ 或 IHC 2+/ISH-) 的不可切除或转移性乳腺癌成人患者, 患者已针对不可切除或转移性疾病接受过内分泌治疗及化疗。</p>	乳腺癌
18	Daunorubicin Hydrochloride and Cytarabine Liposome/ Vyxeos	<p>Indicated for:</p> <p>※ The treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.</p>	<p>适用于:</p> <p>※ 治疗新确诊的治疗相关性急性髓性白血病 (t-AML) 或急性髓性白血病伴骨髓增生异常相关改变 (AML-MRC) 的成人和 1 岁及以上儿童患者。</p>	急性髓性白血病
19	Decitabine and Cedazuridine/ Inqovi	<p>Indicated for:</p> <p>※ The treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-</p>	<p>适用于:</p> <p>※ 治疗既往接受过治疗及未治疗的, 原发性和继发性骨髓增生异常综合征 (MDS) 成人患者, 患者属于法美英 (FAB) 协作组分型中的难治性贫血、难治性贫血伴环</p>	骨髓增生异常综合征

		<p>American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.</p>	<p>状铁粒幼细胞、难治性贫血伴原始细胞增多和慢性粒单核细胞白血病（CMML），以及国际预后评分系统（IPSS）中的中危-1组、中危-2组和高危组。</p>	
20	Denileukin Diftitox-cxdI/ Lymphir	<p>Indicated for:</p> <ul style="list-style-type: none"> <li>※ The treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.</li> </ul>	<p>适用于：</p> <ul style="list-style-type: none"> <li>※ 治疗至少接受过一线全身治疗的复发或难治性I - III期皮肤T细胞淋巴瘤（CTCL）成人患者。</li> </ul>	皮肤T细胞淋巴瘤
21	Dostarlimab-gxly/ Jemperli	<p>Indicated for:</p> <ul style="list-style-type: none"> <li>※ In combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer (EC).</li> <li>※ As a single agent for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (EC), as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.</li> </ul>	<p>适用于：</p> <ul style="list-style-type: none"> <li>※ 联合卡铂和紫杉醇，随后JEMPERLI作为单药，治疗原发性晚期或复发性子宫内膜癌（EC）成人患者。</li> <li>※ 作为单药，治疗在任何情况下既往接受含铂方案治疗期间或之后疾病进展且不适合进行根治性手术或放疗的经FDA批准的检测确认为错配修复缺陷（dMMR）复发性或晚期子宫内膜癌（EC）成人患者。</li> </ul>	子宫内膜癌
		<p>Indicated for:</p> <ul style="list-style-type: none"> <li>※ As a single agent for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.</li> </ul>	<p>适用于：</p> <ul style="list-style-type: none"> <li>※ 作为单药，治疗既往接受治疗期间或之后疾病进展且无理想替代治疗方案的经FDA批准的检测确认为错配修复缺陷（dMMR）复发性或晚期实体瘤成人患者。</li> </ul>	实体瘤
22	Elacestrant/Orserdu	<p>Indicated for:</p> <ul style="list-style-type: none"> <li>※ The treatment of postmenopausal women or adult men, with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.</li> </ul>	<p>适用于：</p> <ul style="list-style-type: none"> <li>※ 治疗ER阳性、HER2阴性、ESR1突变的晚期或转移性乳腺癌绝经后女性或成年男性患者，且患者在接受至少一线内分泌治疗后疾病进展。</li> </ul>	乳腺癌
23	Elotuzumab/Empliciti	<p>Indicated for:</p> <ul style="list-style-type: none"> <li>※ Combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies.</li> <li>※ Combination with pomalidomide and dexamethasone for the treatment</li> </ul>	<p>适用于：</p> <ul style="list-style-type: none"> <li>※ 联合来那度胺和地塞米松，治疗既往已接受过一至三种治疗的多发性骨髓瘤成人患者。</li> <li>※ 联合泊马度胺和地塞米松，治疗既往接受过至少两种治疗（包括来那度胺和蛋</li> </ul>	多发性骨髓瘤



		of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.	白酶体抑制剂) 的多发性骨髓瘤成人患者。	
24	Enasidenib/Idhifa	Indicated for: ※ The treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.	适用于： ※ 治疗经FDA批准的检测确认存在异柠檬酸脱氢酶2 (IDH2) 突变的复发或难治性急性髓性白血病 (AML) 成人患者。	急性髓性白血病
25	Epcoritamab/Epkinly, Tepkinly	Indicated for: ※ The treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.	适用于： ※ 治疗既往接受过二线或多线全身治疗后的非特指型复发或难治性弥漫性大B细胞淋巴瘤 (DLBCL) 成人患者，包括源自惰性淋巴瘤的弥漫性大B细胞淋巴瘤和高级别B细胞淋巴瘤。	弥漫性大B细胞淋巴瘤
		Indicated for: ※ The treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.	适用于： ※ 治疗既往接受过二线或多线全身治疗后的复发或难治性滤泡性淋巴瘤 (FL) 成人患者。	滤泡性淋巴瘤
26	Fedratinib/Inrebic	Indicated for: ※ The treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).	适用于： ※ 治疗中危-2或高危原发性或继发性 (真性红细胞增多症后或原发性血小板增多症后) 骨髓纤维化 (MF) 成人患者。	骨髓纤维化
27	Futibatinib/Lytgobi	Indicated for: ※ The treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.	适用于： ※ 治疗既往接受过治疗的、不可切除的、局部晚期或转移性成纤维细胞生长因子受体2 (FGFR2) 基因融合或其他重排的肝内胆管癌成人患者。	胆管癌
28	Gemtuzumab Ozogamicin/Mylotarg	Indicated for: ※ Treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older.  ※ Treatment of relapsed or refractory CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 2 years and older.	适用于： ※ 治疗新确诊的CD33阳性急性髓性白血病 (AML) 成人和1个月及以上儿童患者。  ※ 治疗复发或难治性CD33阳性急性髓性白血病 (AML) 成人和2岁及以上儿童患者。	急性髓性白血病
29	Glasdegib/Daurismo	Indicated for: ※ In combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are $\geq 75$ years old or who have comorbidities	适用于： ※ 联合低剂量阿糖胞苷，治疗75岁及以上或因合并症而无法接受强化诱导化疗的新确诊急性髓性白血病 (AML) 成人患者。	急性髓性白血病



		that preclude use of intensive induction chemotherapy.		
30	Ibrutumomab Tiuxetan/ Zevalin	<p>Indicated for:</p> <p>※ The treatment of adult patients with:</p> <ul style="list-style-type: none"> <li>• relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL).</li> <li>• previously untreated follicular non-Hodgkin's lymphoma (NHL) who achieve a partial or complete response to first-line chemotherapy.</li> </ul>	<p>适用于:</p> <p>※ 治疗患有以下疾病的成人患者:</p> <ul style="list-style-type: none"> <li>• 复发或难治性、低级别或滤泡性B细胞非霍奇金淋巴瘤（NHL）。</li> <li>• 既往未经治疗的滤泡性非霍奇金淋巴瘤（NHL），且患者在一线化疗后获得部分或完全缓解。</li> </ul>	非霍奇金淋巴瘤
31	Idecabtagene Vicleucel/ Abecma	<p>Indicated for:</p> <p>※ The treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.</p>	<p>适用于:</p> <p>※ 治疗既往接受过二线或二线以上疗法（包括免疫调节剂、蛋白酶体抑制剂和抗CD38单克隆抗体）的复发或难治性多发性骨髓瘤成人患者。</p>	多发性骨髓瘤
32	Idelalisib/Zydelig	<p>Indicated for:</p> <p>※ The treatment of patients with:</p> <ul style="list-style-type: none"> <li>• Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other comorbidities.</li> </ul> <p>Limitations of use:</p> <ul style="list-style-type: none"> <li>• ZYDELIG is not indicated and is not recommended for first-line treatment of any patient, including patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), follicular lymphoma (FL), and other indolent non-Hodgkin lymphomas.</li> <li>• ZYDELIG is not indicated and is not recommended in combination with bendamustine and rituximab, or in combination with rituximab for the treatment of patients with follicular lymphoma (FL), small lymphocytic lymphoma (SLL), and other indolent non-Hodgkin lymphomas.</li> </ul>	<p>适用于:</p> <p>※ 治疗以下患者:</p> <ul style="list-style-type: none"> <li>• 联合利妥昔单抗，治疗因其他合并症而单独使用利妥昔单抗被认为是适当治疗的复发性慢性淋巴细胞白血病（CLL）患者。</li> </ul> <p>使用限制:</p> <ul style="list-style-type: none"> <li>• ZYDELIG不适合也不推荐用于任何患者的一线治疗，包括慢性淋巴细胞白血病（CLL）、小淋巴细胞淋巴瘤（SLL）、滤泡性淋巴瘤（FL）和其他惰性非霍奇金淋巴瘤患者。</li> <li>• ZYDELIG不适合也不推荐联合苯达莫司汀和利妥昔单抗，或联合利妥昔单抗治疗滤泡性淋巴瘤（FL）、小淋巴细胞淋巴瘤（SLL）和其他惰性非霍奇金淋巴瘤患者。</li> </ul>	慢性淋巴细胞白血病
33	Imetelstat/Rytelio	<p>Indicated for:</p> <p>※ The treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).</p>	<p>适用于:</p> <p>※ 治疗低危至中危-1骨髓增生异常综合征（MDS）成人患者，患者存在输血依赖性贫血（8周内需输注4个单位及以上红细胞），且已对红细胞生成刺激剂（ESA）无应答、失去应答或不适用。</p>	骨髓增生异常综合征
34	Iobenguane I-131/Azedra	Indicated for:	适用于:	嗜铬细胞瘤/



		※ The treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy.	※ 治疗需要全身抗癌治疗的间碘苄胍显像阳性、不可切除、局部晚期或转移性嗜铬细胞瘤或副神经节瘤成人和12岁及以上儿童患者。	副神经节瘤
35	Lifileucel/Amtagvi	Indicated for: ※ The treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.	适用于： ※ 治疗既往接受过PD-1抑制剂治疗的、不可切除或转移性黑色素瘤成人患者，若患者为BRAF V600突变阳性，则需已接受BRAF抑制剂（可合并或不合并MEK抑制剂）治疗。	黑色素瘤
36	Lisocabtagene Maraleucel/Breyanzi	Indicated for: ※ The treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have: <ul style="list-style-type: none"><li>refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or</li><li>refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age; or</li><li>relapsed or refractory disease after two or more lines of systemic therapy.</li></ul> Limitations of Use: BREYANZI is not indicated for the treatment of patients with primary central nervous system lymphoma.	适用于： ※ 治疗大B细胞淋巴瘤(LBCL)成人患者，包括非特指型弥漫性大B细胞淋巴瘤(DLBCL)（包括源自惰性淋巴瘤的弥漫性大B细胞淋巴瘤）、高级别B细胞淋巴瘤、原发性纵隔大B细胞淋巴瘤和3B级滤泡性淋巴瘤，且： <ul style="list-style-type: none"><li>一线化学免疫疗法难治或接受一线化学免疫疗法后12个月内复发；或</li><li>一线化学免疫疗法难治或接受一线化学免疫疗法后复发且因合并症或年龄不适合进行造血干细胞移植(HSCT)；或</li><li>既往接受二线或二线以上全身治疗后复发或难治。</li></ul> 使用限制：BREYANZI不适用于治疗原发性中枢神经系统淋巴瘤患者。	大B细胞淋巴瘤
		Indicated for: ※ The treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least 2 prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor.	适用于： ※ 治疗既往至少接受过二线疗法，包括布鲁顿酪氨酸激酶(BTK)抑制剂和B细胞淋巴瘤2(BCL-2)抑制剂的复发或难治性慢性淋巴细胞白血病(CLL)或小淋巴细胞淋巴瘤(SLL)成人患者。	慢性淋巴细胞白血病/小淋巴细胞淋巴瘤
		Indicated for: ※ The treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received 2 or more prior lines of systemic therapy.	适用于： ※ 治疗既往接受过二线或二线以上全身治疗的复发或难治性滤泡性淋巴瘤(FL)成人患者。	滤泡性淋巴瘤

		<p>Indicated for:</p> <p>※ The treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least 2 prior lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor.</p>	<p>适用于:</p> <p>※ 治疗既往接受过至少二线全身治疗，包括布鲁顿酪氨酸激酶 (BTK) 抑制剂的复发或难治性套细胞淋巴瘤 (MCL) 成人患者。</p>	套细胞淋巴瘤
37	Lutetium Lu 177 Dotatate/ Lutathera	<p>Indicated for:</p> <p>※ The treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors.</p>	<p>适用于:</p> <p>※ 治疗生长抑素受体阳性的胃肠胰神经内分泌肿瘤 (GEP-NETs) 成人和12岁及以上儿童患者，包括前肠、中肠和后肠神经内分泌肿瘤。</p>	神经内分泌肿瘤
38	Lutetium Lu 177 Vipivotide Tetraxetan/Pluvicto	<p>Indicated for:</p> <p>※ The treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy, and:</p> <ul style="list-style-type: none"> <li>• are considered appropriate to delay taxane-based chemotherapy, or</li> <li>• have received prior taxane-based chemotherapy.</li> </ul>	<p>适用于:</p> <p>※ 治疗已接受雄激素受体通路抑制剂 (ARPI) 治疗的前列腺特异性抗原 (PSMA) 阳性的转移性去势抵抗性前列腺癌 (mCRPC) 成人患者，且：</p> <ul style="list-style-type: none"> <li>• 患者被认为适合延后使用紫杉烷类化疗；或</li> <li>• 患者既往接受过紫杉烷类化疗。</li> </ul>	前列腺癌
39	Midostaurin/Rydapt	<p>Indicated for:</p> <p>※ The treatment of adult patients with:</p> <ul style="list-style-type: none"> <li>• Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.</li> </ul> <p>Limitations of Use: RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with acute myeloid leukemia (AML).</p>	<p>适用于:</p> <p>※ 治疗患有以下疾病的成人患者：</p> <ul style="list-style-type: none"> <li>• 联合标准方案阿糖胞苷和柔红霉素诱导治疗及阿糖胞苷巩固治疗，经FDA批准的检测确认为FLT3突变的新确诊急性髓性白血病 (AML)。</li> </ul> <p>使用限制：RYDAPT不适用于急性髓性白血病 (AML) 患者的单药诱导疗法。</p>	急性髓性白血病
		<p>Indicated for:</p> <p>※ The treatment of adult patients with:</p> <ul style="list-style-type: none"> <li>• Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).</li> </ul>	<p>适用于:</p> <p>※ 治疗患有以下疾病的成人患者：</p> <ul style="list-style-type: none"> <li>• 侵袭性系统性肥大细胞增多症 (ASM)、系统性肥大细胞增多症伴相关血液肿瘤 (SM-AHN) 或肥大细胞白血病 (MCL)。</li> </ul>	侵袭性系统性肥大细胞增多症 / 系统性肥大细胞增多症伴相关血液肿瘤 / 肥大细胞白血病
40	Mitomycin/Jelmyto	<p>Indicated for:</p> <p>※ The treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC).</p>	<p>适用于:</p> <p>※ 治疗低级别上尿路尿路上皮癌 (LG-UTUC) 成人患者。</p>	上尿路尿路上皮癌

41	Momelotinib/ Ojjaara, Omjara	Indicated for: ※ The treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.	适用于： ※ 治疗伴有贫血的中危或高危骨髓纤维化 (MF) 成人患者，包括原发性骨髓纤维化或继发性骨髓纤维化【真性红细胞增多症后 (PV) 或原发性血小板增多症后 (ET)】。	骨髓纤维化
42	Nadofaragene Firadenovec-vncg/Adstiladrin	Indicated for: ※ The treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.	适用于： ※ 治疗高危、对卡介苗 (BCG) 无应答的非肌层浸润性膀胱癌 (NMIBC) 成人患者，无论其是否伴有乳头状肿瘤的原位癌 (CIS)。	膀胱癌
43	Nelarabine/Arranon	Indicated for: ※ The treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.	适用于： ※ 治疗既往至少接受过两种化疗方案后疾病无应答或复发的T细胞急性淋巴细胞白血病 (T-ALL) 和T细胞淋巴母细胞淋巴瘤 (T-LBL) 成人和1岁及以上儿童患者。	T细胞急性淋巴细胞白血病/ T淋巴母细胞淋巴瘤
44	Nilutamide/Nilandron	Indicated for: ※ Use in combination with surgical castration for the treatment of metastatic prostate cancer (Stage D2).	适用于： ※ 联合手术去势，治疗转移性前列腺癌 (D2期)。	前列腺癌
45	Nirogacestat/Ogsiveo	Indicated for: ※ Adult patients with progressing desmoid tumors who require systemic treatment.	适用于： ※ 需要全身治疗的进展性硬纤维瘤成人患者。	硬纤维瘤
46	Nivolumab & Relatlimab-rmbw/Opdualag	Indicated for: ※ The treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.	适用于： ※ 治疗不可切除或转移性黑色素瘤成人和12岁及以上儿童患者。	黑色素瘤
47	Nogapendekin Alfa Inbakicept-pmln/Anktiva	Indicated: ※ With Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.	适用于： ※ 联合卡介苗 (BCG)，治疗对卡介苗 (BCG) 无应答的非肌层浸润性膀胱癌 (NMIBC) 成人患者，无论其是否伴有乳头状肿瘤的原位癌 (CIS)。	膀胱癌
48	Obecabtagene Autoleucel/Aucatzy1	Indicated for: ※ The treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).	适用于： ※ 治疗复发或难治性B细胞前体急性淋巴细胞白血病 (ALL) 成人患者。	急性淋巴细胞白血病
49	Olutasidenib/Rezlidhia	Indicated for: ※ The treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.	适用于： ※ 治疗经FDA批准的检测认为易感IDH1突变的复发或难治性急性髓性白血病 (AML) 成人患者。	急性髓性白血病
50	Pacritinib/Vonjo	Indicated for: ※ The treatment of adults with intermediate or highrisk primary or	适用于： ※ 治疗血小板计数低于 $50 \times 10^9/L$ 的中危或高危原发性	骨髓纤维化

		secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below $50 \times 10^9/L$ .	或继发性【真性红细胞增多症后 (PV) 或原发性血小板增多症后 (ET) 】骨髓纤维化 (MF) 成人患者。	
51	Panitumumab/Vectibix	<p>Indicated for:</p> <p>※ The treatment of adult patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test) Metastatic Colorectal Cancer (mCRC)*:</p> <ul style="list-style-type: none"> <li>• In combination with FOLFOX for first-line treatment.</li> <li>• As monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy.</li> </ul> <p>※ In combination with sotorasib, for the treatment of adult patients with KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC), as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.</p> <p>*Limitation of Use: VECTIBIX is not indicated for the treatment of patients with RAS-mutant Metastatic Colorectal Cancer (mCRC) unless used in combination with sotorasib in KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC). VECTIBIX is not indicated for the treatment of patients with Metastatic Colorectal Cancer (mCRC) for whom RAS mutation status is unknown.</p>	<p>适用于:</p> <p>※ 治疗野生型RAS (经FDA批准的检测确认KRAS和NRAS为野生型) 转移性结直肠癌 (mCRC) 成人患者:</p> <ul style="list-style-type: none"> <li>• 联合FOLFOX化疗方案用于一线治疗。</li> <li>• 既往接受氟嘧啶、奥沙利铂和含伊立替康方案的化疗后疾病进展后的单药治疗。</li> </ul> <p>※ 联合sotorasib, 治疗经FDA批准的检测确认KRAS G12C突变、既往接受过含氟嘧啶、奥沙利铂和伊立替康方案化疗的转移性结直肠癌 (mCRC) 成人患者。</p> <p>使用限制: 除了联合sotorasib治疗KRAS G12C突变的转移性结直肠癌 (mCRC) 外, VECTIBIX不适用于治疗RAS突变的转移性结直肠癌 (mCRC) 患者。</p> <p>VECTIBIX不适用于治疗RAS突变状态未知的转移性结直肠癌 (mCRC) 患者。</p>	结直肠癌
52	Quizartinib/Vanflyta	<p>Indicated for:</p> <p>※ In combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test.</p> <p>Limitations of Use:</p> <p>VANFLYTA is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation (HSCT); improvement in overall survival with VANFLYTA in this setting has not been demonstrated.</p>	<p>适用于:</p> <p>※ 联合标准阿糖胞苷和蒽环类诱导治疗以及联合阿糖胞苷巩固治疗, 并作为巩固治疗后的单药维持治疗经FDA批准的检测确认为FLT3内部串联重复 (ITD) 突变的新确诊急性髓性白血病 (AML) 成人患者。</p> <p>使用限制:</p> <p>VANFLYTA不适合在同种异体造血干细胞移植 (HSCT) 后作为单药维持治疗; 尚未证明VANFLYTA在这种情况下可改善总生存期。</p>	急性髓性白血病
53	Relugolix/Orgovyx	Indicated for:	适用于:	前列腺癌



友邦保险

友邦人寿保险有限公司

		※ The treatment of adult patients with advanced prostate cancer.	※ 治疗晚期前列腺癌成人患者。	
54	Repotrectinib/Augtyro	Indicated for: ※ The treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).  Indicated for: ※ The treatment of adult and pediatric patients 12 years of age and older with solid tumors that: <ul style="list-style-type: none"><li>• have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion and</li><li>• are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity.</li><li>• have progressed following treatment or have no satisfactory alternative therapy.</li></ul>	适用于： ※ 治疗局部晚期或转移性ROS1阳性非小细胞肺癌（NSCLC）成人患者。  适用于： ※ 治疗符合以下条件的实体瘤成人和12岁及以上儿童患者： <ul style="list-style-type: none"><li>• 存在神经营养性酪氨酸受体激酶（NTRK）基因融合，且</li><li>• 为局部晚期或转移性，或手术切除可能导致严重功能损害。</li><li>• 既往接受治疗后疾病进展，或无其他令人满意的替代治疗方案。</li></ul>	非小细胞肺癌  实体瘤
55	Retifanlimab-dlwr/Zynzyz	Indicated for: ※ The treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).  Indicated for: ※ In combination with carboplatin and paclitaxel for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC).  ※ As a single agent for the treatment of adult patients with locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) with disease progression on or intolerance to platinum-based chemotherapy.	适用于： ※ 治疗转移性或复发性局部晚期Merkel细胞癌（MCC）成人患者。  适用于： ※ 联合卡铂和紫杉醇，一线治疗不可手术的局部复发或转移性肛管鳞状细胞癌（SCAC）成人患者。  ※ 作为单药，治疗在接受含铂化疗期间疾病进展或对含铂化疗不耐受的局部复发或转移性肛管鳞状细胞癌（SCAC）成人患者。	Merkel细胞癌  肛管鳞状细胞癌
56	Revumenib/Revuforj	Indicated for: ※ The treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.	适用于： ※ 治疗赖氨酸甲基转移酶2A基因（KMT2A）易位的复发或难治性急性白血病成人和1岁及以上儿童患者。	急性白血病
57	Romidepsin/Istodax	Indicated for: ※ The treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy.	适用于： ※ 治疗既往至少接受过一线全身治疗的皮肤T细胞淋巴瘤（CTCL）成人患者。	皮肤T细胞淋巴瘤
58	Rucaparib/Rubraca	Indicated for: ※ The treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-	适用于： ※ 治疗伴有BRCA基因有害突变（胚系和/或体细胞）的转移性去势抵抗性前列腺癌（mCRPC）成人患者，患者既往接受过雄激素受体靶向疗法和紫杉烷类化疗。根	前列腺癌

		<p>directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA.</p> <p>Indicated for:</p> <ul style="list-style-type: none"> <li>※ The maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.</li> </ul>	<p>据FDA批准的RUBRACA伴随诊断选择患者治疗。</p> <p>适用于：</p> <ul style="list-style-type: none"> <li>※ 对含铂化疗完全或部分缓解的，存在BRCA基因有害突变（胚系和/或体细胞）的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者的维持治疗。</li> </ul>	
59	Sirolimus Protein-bound Particles for Injectable Suspension (Albumin-bound)/Fyarro	<p>Indicated for:</p> <ul style="list-style-type: none"> <li>※ The treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).</li> </ul>	<p>适用于：</p> <ul style="list-style-type: none"> <li>※ 治疗局部晚期不可切除或转移性恶性血管周上皮样细胞瘤（PEComa）成人患者。</li> </ul>	血管周上皮样细胞瘤
60	Sotorasib/Lumakras	<p>Indicated for:</p> <ul style="list-style-type: none"> <li>※ As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.</li> </ul> <p>Indicated for:</p> <ul style="list-style-type: none"> <li>※ In combination with panitumumab, for the treatment of adult patients with KRAS G12C-mutated mCRC as determined by an FDA approved-test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.</li> </ul>	<p>适用于：</p> <ul style="list-style-type: none"> <li>※ 作为单药，治疗经FDA批准的检测确认为KRAS G12C突变且既往至少接受过一线全身治疗的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者。</li> </ul> <p>适用于：</p> <ul style="list-style-type: none"> <li>※ 联合panitumumab，治疗经FDA批准的检测确认为KRAS G12C突变且既往接受过含氟嘧啶、奥沙利铂和伊立替康方案化疗的转移性结直肠癌（mCRC）成人患者。</li> </ul>	非小细胞肺癌 结直肠癌
61	Tagraxofusp-erzs/ Elzonris	<p>Indicated for:</p> <ul style="list-style-type: none"> <li>※ The treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.</li> </ul>	<p>适用于：</p> <ul style="list-style-type: none"> <li>※ 治疗母细胞性浆细胞样树突状细胞肿瘤（BPDCN）成人和2岁及以上儿童患者。</li> </ul>	母细胞性浆细胞样树突状细胞肿瘤
62	Talimogene Laherparepvec/ Imlygic	<p>Indicated for:</p> <ul style="list-style-type: none"> <li>※ The local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.</li> </ul> <p>Limitations of use: IMLYGIC has not been shown to improve overall survival or have an effect on visceral metastases.</p>	<p>适用于：</p> <ul style="list-style-type: none"> <li>※ 初次手术后复发的黑色素瘤患者，局部治疗其不可手术切除的皮肤、皮下及淋巴结病灶。</li> </ul> <p>使用限制：</p> <ul style="list-style-type: none"> <li>尚未证明IMLYGIC能够改善总体生存期，亦未证实其对内脏转移病灶具有疗效。</li> </ul>	黑色素瘤
63	Tarlatamab-dlle/ Imdelltra	<p>Indicated for:</p> <ul style="list-style-type: none"> <li>※ The treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.</li> </ul>	<p>适用于：</p> <ul style="list-style-type: none"> <li>※ 治疗在含铂化疗期间或之后疾病进展的广泛期小细胞肺癌（ES-SCLC）成人患者。</li> </ul>	小细胞肺癌



64	Tebentafusp-tebn/ Kimmtrak	Indicated for: ※ The treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.	适用于： ※ 治疗HLA-A*02:01阳性不可切除或转移性葡萄膜黑色素瘤成人患者。	葡萄膜黑色素瘤
65	Temsirolimus/Torisel	Indicated for: ※ Treatment of advanced renal cell carcinoma.	适用于： ※ 治疗晚期肾细胞癌。	肾细胞癌
66	Tisagenlecleucel/Kymriah	Indicated for: ※ The treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.  Limitations of Use: KYMRIAH is not indicated for treatment of patients with primary central nervous system lymphoma.	适用于： ※ 治疗既往接受过二线或二线以上全身治疗后复发或难治性 (r/r) 大B细胞淋巴瘤成人患者，包括非特指型弥漫性大B细胞淋巴瘤 (DLBCL)、高级别B细胞淋巴瘤和由滤泡性淋巴瘤转化而来的弥漫性大B细胞淋巴瘤 (DLBCL)。  使用限制： KYMRIAH 不适用于治疗原发性中枢神经系统淋巴瘤患者。	大B细胞淋巴瘤
		Indicated for: ※ The treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.	适用于： ※ 治疗难治性或处于第二次及以上复发的25岁及以下B细胞前体急性淋巴细胞白血病 (ALL) 患者。	急性淋巴细胞白血病
		Indicated for: ※ The treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.	适用于： ※ 治疗既往接受过二线或二线以上全身治疗后复发或难治性滤泡性淋巴瘤 (FL) 成人患者。	滤泡性淋巴瘤
67	Tisotumab Vedotin-tftv/ Tivdak	Indicated for: ※ The treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.	适用于： ※ 治疗化疗期间或之后疾病进展的复发或转移性宫颈癌成人患者。	宫颈癌
68	Tivozanib/Fotivda	Indicated for: ※ The treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.	适用于： ※ 治疗既往接受过二线或二线以上全身治疗的复发或难治性晚期肾细胞癌 (RCC) 成人患者。	肾细胞癌
69	Tovorafenib/Ojemda	Indicated for: ※ The treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.	适用于： ※ 治疗BRAF融合或重排，或BRAF V600突变的复发或难治性低级别胶质瘤 (LGG) 6个月及以上患者。	低级别胶质瘤
70	Tremelimumab-actl/Imjudo	Indicated for: ※ In combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).	适用于： ※ 联合度伐利尤单抗，治疗不可切除的肝细胞癌 (uHCC) 成人患者。	肝细胞癌

		<p>Indicated for:</p> <p>※ In combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.</p>	<p>适用于:</p> <p>※ 联合度伐利尤单抗和含铂化疗，治疗无敏感性EGFR突变或ALK基因异常的转移性非小细胞肺癌（NSCLC）成人患者。</p>	非小细胞肺癌
71	Treosulfan/Grafapex	<p>Indicated for:</p> <p>※ Use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult and pediatric patients 1 year of age and older with acute myeloid leukemia (AML).</p> <p>※ Use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult and pediatric patients 1 year of age and older with myelodysplastic syndrome (MDS).</p>	<p>适用于:</p> <p>※ 联合氟达拉滨，作为急性髓性白血病（AML）成人和1岁及以上儿童患者的异基因造血干细胞移植（alloHSCT）的预处理方案。</p> <p>※ 联合氟达拉滨，作为骨髓增生异常综合征（MDS）成人和1岁及以上儿童患者的异基因造血干细胞移植（alloHSCT）的预处理方案。</p>	急性髓性白血病/骨髓增生异常综合征
72	Tucatinib/Tukysa	<p>Indicated for:</p> <p>※ In combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.</p>	<p>适用于:</p> <p>※ 联合曲妥珠单抗和卡培他滨，治疗既往在转移性阶段接受过一种或多种抗HER2治疗方案的晚期不可切除或转移性HER2阳性乳腺癌成人患者，包括伴有脑转移的患者。</p>	乳腺癌
		<p>Indicated for:</p> <p>※ In combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.</p>	<p>适用于:</p> <p>※ 联合曲妥珠单抗，治疗在接受含氟嘧啶、奥沙利铂和伊立替康方案的化疗后疾病进展的RAS野生型、HER2阳性、不可切除或转移性结直肠癌成人患者。</p>	结直肠癌
73	Vandetanib/Caprelsa	<p>Indicated for:</p> <p>※ The treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.</p> <p>Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA.</p>	<p>适用于:</p> <p>※ 治疗不可切除的局部晚期或转移性有症状或进展性甲状腺髓样癌。</p> <p>仅在审慎考虑CAPRELSA治疗的相关风险后，才可对惰性、无症状或疾病进展缓慢的患者使用CAPRELSA。</p>	甲状腺髓样癌
74	Vismodegib/Erivedge	<p>Indicated for:</p> <p>※ The treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell</p>	<p>适用于:</p> <p>※ 治疗转移性基底细胞癌或手术后复发的或不适合手术</p>	基底细胞癌

		carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation.	且不适合放疗的局部晚期基底细胞癌成人患者。	
75	Vorinostat/Zolinza	Indicated for: ※ The treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.	适用于: ※ 治疗在接受二线全身治疗期间或之后出现疾病进展、持续或复发的皮肤T细胞淋巴瘤（CTCL）患者的皮肤表现。	皮肤T细胞淋巴瘤
76	Zenocutuzumab-zbco/ Bizengri	Indicated for: ※ The treatment of adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.	适用于: ※ 治疗伴有神经调节蛋白1 (NRG1) 基因融合、且在既往全身治疗期间或之后疾病进展的晚期、不可切除或转移性非小细胞肺癌 (NSCLC) 成人患者。	非小细胞肺癌
		Indicated for: ※ The treatment of adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.	适用于: ※ 治疗伴有神经调节蛋白1 (NRG1) 基因融合、且在既往全身治疗期间或之后疾病进展的晚期、不可切除或转移性胰腺癌成人患者。	胰腺癌
77	Ziv-aflibercept/Zaltrap	Indicated for: ※ In combination with fluorouracil, leucovorin, irinotecan (FOLFIRI), for the treatment of patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen.	适用于: ※ 联合氟尿嘧啶、亚叶酸钙和伊立替康（FOLFIRI方案），治疗对含奥沙利铂方案耐药或在其治疗后疾病进展的转移性结直肠癌患者。	结直肠癌

（此页内容结束）